SG11201809229VA - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ucb
- rule
- freeze
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
| PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809229VA true SG11201809229VA (en) | 2018-11-29 |
Family
ID=56320265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809229VA SG11201809229VA (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11407835B2 (enExample) |
| EP (1) | EP3454899B1 (enExample) |
| JP (1) | JP7126454B2 (enExample) |
| KR (1) | KR102436694B1 (enExample) |
| CN (1) | CN109069643A (enExample) |
| AR (1) | AR108449A1 (enExample) |
| AU (1) | AU2017264553A1 (enExample) |
| BR (1) | BR112018072264A2 (enExample) |
| CA (1) | CA3022124A1 (enExample) |
| CL (1) | CL2018003178A1 (enExample) |
| CO (1) | CO2018011733A2 (enExample) |
| EA (1) | EA201892446A1 (enExample) |
| ES (1) | ES2977545T3 (enExample) |
| GB (1) | GB201608323D0 (enExample) |
| IL (1) | IL262654A (enExample) |
| MX (1) | MX2018013215A (enExample) |
| SG (1) | SG11201809229VA (enExample) |
| WO (1) | WO2017194646A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| BR112020019065A2 (pt) * | 2018-03-23 | 2020-12-29 | AbbVie Deutschland GmbH & Co. KG | Formulações de anticorpo anti-tau aquosas estáveis |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| CA3174988A1 (en) * | 2020-03-11 | 2021-09-16 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| KR20220001482A (ko) * | 2020-06-29 | 2022-01-05 | 한올바이오파마주식회사 | 항-FcRn 항체에 대한 제형 |
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| PE20241936A1 (es) | 2021-12-01 | 2024-09-24 | UCB Biopharma SRL | Formulaciones que comprenden fab-peg |
| WO2023224112A1 (ja) * | 2022-05-20 | 2023-11-23 | 株式会社ダイセル | 液状医薬組成物 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| CN115708810A (zh) * | 2022-11-03 | 2023-02-24 | 浙江新码生物医药有限公司 | 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
| JP2026508415A (ja) * | 2023-03-08 | 2026-03-10 | イムノバント サイエンシズ ゲーエムベーハー | ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法 |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| AU2007251122B2 (en) * | 2006-05-12 | 2013-01-10 | Bharat Biotech International Limited | A composition useful as a vaccine |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| WO2012135408A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| JP6265970B2 (ja) | 2012-03-26 | 2018-01-24 | サノフイ | 安定なＩｇＧ４に基づく結合剤の製剤 |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| WO2014093206A1 (en) | 2012-12-13 | 2014-06-19 | Merck Sharp & Dohme Corp. | Lyophilized spherical pellets of anti-il-23 antibodies |
| WO2015121318A1 (en) * | 2014-02-12 | 2015-08-20 | Sanofi | Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations |
| US20170247460A1 (en) | 2014-10-18 | 2017-08-31 | Pfizer Inc. | Anti-il-7r antibody compositions |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en not_active Ceased
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/ko not_active Expired - Fee Related
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/ja active Active
- 2017-05-11 AR ARP170101248A patent/AR108449A1/es not_active Application Discontinuation
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/zh active Pending
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 ES ES17725544T patent/ES2977545T3/es active Active
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/pt not_active IP Right Cessation
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/es unknown
- 2017-05-11 EA EA201892446A patent/EA201892446A1/ru unknown
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/es unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2018011733A2 (es) | 2019-02-08 |
| IL262654A (en) | 2018-12-31 |
| US20200048346A1 (en) | 2020-02-13 |
| WO2017194646A1 (en) | 2017-11-16 |
| CL2018003178A1 (es) | 2019-02-01 |
| RU2018141591A (ru) | 2020-06-15 |
| MX2018013215A (es) | 2019-02-21 |
| US11407835B2 (en) | 2022-08-09 |
| ES2977545T3 (es) | 2024-08-26 |
| CA3022124A1 (en) | 2017-11-16 |
| GB201608323D0 (en) | 2016-06-29 |
| EP3454899C0 (en) | 2024-03-20 |
| BR112018072264A2 (pt) | 2019-02-12 |
| KR102436694B1 (ko) | 2022-08-25 |
| KR20190008320A (ko) | 2019-01-23 |
| RU2018141591A3 (enExample) | 2021-01-13 |
| EA201892446A1 (ru) | 2019-04-30 |
| EP3454899B1 (en) | 2024-03-20 |
| JP2019514998A (ja) | 2019-06-06 |
| JP7126454B2 (ja) | 2022-08-26 |
| AU2017264553A1 (en) | 2018-12-13 |
| AR108449A1 (es) | 2018-08-22 |
| EP3454899A1 (en) | 2019-03-20 |
| CN109069643A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201804961UA (en) | Formulations with reduced degradation of polysorbate | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides |